- Home
- LX vs ARVN Comparison
LX vs ARVN Comparison
Compare LX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- ARVN
- Stock Information
- Founded
- LX 2013
- ARVN 2015
- Country
- LX China
- ARVN United States
- Employees
- LX N/A
- ARVN N/A
- Industry
- LX Finance: Consumer Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- ARVN Health Care
- Exchange
- LX Nasdaq
- ARVN Nasdaq
- Market Cap
- LX 1.4B
- ARVN 1.4B
- IPO Year
- LX 2017
- ARVN 2018
- Fundamental
- Price
- LX $9.36
- ARVN $17.77
- Analyst Decision
- LX
- ARVN Strong Buy
- Analyst Count
- LX 0
- ARVN 12
- Target Price
- LX N/A
- ARVN $58.82
- AVG Volume (30 Days)
- LX 3.5M
- ARVN 1.1M
- Earning Date
- LX 03-19-2025
- ARVN 02-11-2025
- Dividend Yield
- LX 1.47%
- ARVN N/A
- EPS Growth
- LX N/A
- ARVN N/A
- EPS
- LX 0.65
- ARVN N/A
- Revenue
- LX $2,003,592,128.00
- ARVN $263,399,999.00
- Revenue This Year
- LX $10.54
- ARVN N/A
- Revenue Next Year
- LX $5.22
- ARVN $1.63
- P/E Ratio
- LX $14.46
- ARVN N/A
- Revenue Growth
- LX 11.56
- ARVN 235.54
- 52 Week Low
- LX $1.56
- ARVN $16.61
- 52 Week High
- LX $9.62
- ARVN $51.51
- Technical
- Relative Strength Index (RSI)
- LX 71.87
- ARVN 44.33
- Support Level
- LX $7.57
- ARVN $17.19
- Resistance Level
- LX $9.00
- ARVN $20.38
- Average True Range (ATR)
- LX 0.53
- ARVN 1.38
- MACD
- LX 0.04
- ARVN 0.08
- Stochastic Oscillator
- LX 88.33
- ARVN 30.77
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.